International Journal of Nanomedicine · 2024 · 45 citations · 120 references
PharmacyPharmaceuticsPharmacologyBone MetabolismDrug DeliveryNanoparticle Drug DeliveryNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNanoparticle DesignOsteoporosisOsteoporosis PharmacotherapyBone Resorption InhibitionBone Tissue TargetingDrug Delivery NanocarriersMultifunctional NanoparticlesNanoparticle Drug Delivery SystemsNanoparticle Drug TargetingNanoparticlesPostmenopausal Osteoporosis Treatment
Osteoporosis (OP) affects millions of people worldwide, especially postmenopausal women and the elderly. Although current available anti-OP agents can show promise in slowing down bone resorption, most are not specifically delivered to the hard tissue, causing significant toxicity. A bone-targeted nanodrug delivery system can reduce side effects and precisely deliver drug candidates to the bone. This review focuses on the progress of bone-targeted nanoparticles in OP therapy. We enumerate the existing OP medications, types of bone-targeted nanoparticles and categorize pairs of the most common bone-targeting functional groups. Finally, we summarize the potential use of bone-targeted nanoparticles in OP treatment. Ongoing research into the development of targeted ligands and nanocarriers will continue to expand the possibilities of OP-targeted therapies into clinical application.
120
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis
Li Ma, Jennifer J. Young, Harsha Prabhala et al. · Nature Cell Biology · 2010 · 1.3K citations · Full text
Pauline M. Camacho, Steven M. Petak, Neil Binkley et al. · Endocrine Practice · 2016 · 1.1K citations